Liver cancer detection is automated

Share This Post

CT scan (Computed Tomography) is basically an X-ray image, which can be used to provide clinicians with a detailed view of our internal organs, and can usually diagnose various forms of cancer. Previously, the use of CT to diagnose liver cancer was hindered to some extent by changes in the shape and structure of individual livers and the similarity of tissues in adjacent organs in CT images.

Amita Das of the Technical Education and Research Institute of the Department of Electronic and Communication Engineering at Siksha’O’Anusandhan University in Orissa, as well as Electrical Engineering at SCB Medical School and DY Patil Ramrao Adik Institute of Technology in Nerul, New Mumbai The department has developed a new texture analysis technology based on adaptive fuzzy clustering, which can be used to classify abdominal CT scans to diagnose liver cancer. This method is based on the extracted texture, morphology, and statistical features from the scan and using them as input, which can judge the neural network classifier to distinguish between benign and malignant liver tumors.

Today, they tested their method with a series of 45 images and studied sensitivity, specificity, and accuracy. The team was able to achieve nearly 99% accuracy in detecting tumors, and this result is already very good. The researchers’ next plan is to provide more data and training for the system, thereby further improving the reliability of the technology and developing an automatic diagnostic method that does not have the possibility of human error.


For details on best options for liver cancer treatment, do call us at +91 96 1588 1588 or write to

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form